subject: Therapeutic Cancer Vaccines In Phase-3 Clinical Trials Influencing Market Dynamics [print this page] A new research report from RNCOS reveals that 18 promising studies in phase-3 clinical trials are expected to yield possible therapeutic cancer vaccine products in the very near future. Currently, more than 30% of the therapeutic cancer vaccines in phase-3 clinical trials are for the treatment of lung cancer. This is reflective of the high demand that exists owing to the high incidence and prevalence of lung cancer in US. But for other leading cancer namely cancer of the prostate, breast, colon & rectum and corpus & uterus, NOS; there are few vaccine candidates in advanced phases of clinical trials. The most neglected segment is of the cancer of corpus & uterus, NOS (endometrial cancer) where no candidate exists in phase-3 clinical trial.
Further analysis reveals Lucanix and Stimuvax as very promising candidates. Currently in phase-3 clinical trial, NovaRx Corporations Lucanix is an allogeneic therapeutic vaccine, which consists of Non-Small Cell Lung Cancer cells derived from lung cancer patients. The drug is a very promising candidate with encouraging results and few side-effects. Moreover, Stimuvax, being developed by Merck under a license agreement with Oncothyreon is also reporting fabulous results. Merck is currently conducting two phase-3 trials of Stimuvax. This therapeutic cancer vaccine has been designed to induce an immune response to cancer cells that express MUC1, a protein antigen widely expressed on common cancers. It is currently being investigated as a potential clinical therapy candidate and if all goes well, can be expected to hit market by 2016-17.
The report entitled "US Cancer Vaccines Market Analysis, provides an analysis of the market drivers, current market size, and future estimates. It also provides the key constraints faced by these cancer vaccine products that can hinder its market growth in the future. Moreover, an in-depth analysis of all the candidate cancer vaccines in various phases of clinical trials for most prevalent cancers in US has been done to identify diverse opportunities for players.
Further, the report provides competitive analysis of the promising players in the market along with their key strategies for business expansion. The regulatory environment detailing the whole cancer vaccine approval process along with FDAs guidelines to the industry for clinical proceedings of cancer therapeutic vaccines has also been provided.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM457.htm
Some of our Related Reports are:
- Global Vaccine Market Forecast to 2013 (http://www.rncos.com/Report/IM357.htm)
- Global Influenza Vaccine Market Analysis (http://www.rncos.com/Report/IM356.htm)
- Global Telemedicine Market Analysis (http://www.rncos.com/Report/IM331.htm)
- Personalized Medicine Market Analysis (http://www.rncos.com/Report/IM305.htm)
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
About RNCOS
RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.
by: Shushmul Maheshwari
welcome to Insurances.net (https://www.insurances.net)
